It would be irresponsible to pay a dividend at this time. Having a strong financial position gives the company more options (ability to fund more pre-clinical work, preparations for our first 2591 Phase 3 trial, and provides potential negotiation leverage)
Assuming we don't get bought out, a dividend would be long way away. They'd sooner do a buy-back but then that would only if there are no better usages for the cash (there's plenty of right now)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.26 |
Change
-0.280(2.23%) |
Mkt cap ! $1.525B | |||
| Open | High | Low | Value | Volume |
| $12.45 | $12.45 | $11.88 | $6.952M | 570.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 231 | $12.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.32 | 1979 | 2 |
View Market Depth
| Last trade - 16.13pm 23/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |